How far have we achieved by systemic therapy for recurrent/metastatic nasopharyngeal carcinoma? by Lee, VHF
Title How far have we achieved by systemic therapy forrecurrent/metastatic nasopharyngeal carcinoma?
Author(s) Lee, VHF
Citation Translational Cancer Research, 2016, v. 5 n. suppl. 7, p. S1424-S1427
Issued Date 2016
URL http://hdl.handle.net/10722/239532
Rights Creative Commons: Attribution 3.0 Hong Kong License
© Translational Cancer Research. All rights reserved. Transl Cancer Res 2016;5(Suppl 7):S1424-S1427 tcr.amegroups.com
Nasopharyngeal carcinoma of undifferentiated type is 
distinctive in terms of radical and geographical distribution, 
with highest incidence in Southern China, Taiwan 
and Singapore, followed by North Africa and Alaska. 
Radiotherapy with contemporary techniques like intensity-
modulated radiation therapy is the mainstay of treatment 
for early-stage disease, while concurrent chemoradiation 
with or without adjunct chemotherapy is indicated in 
locoregionally advanced disease (1). Nevertheless, about 
30% of patients develop recurrence or metastasis despite 
intensive radical treatment (2). Though most of these 
relapsed patients have an unfavorable survival outcome, 
their survival can be significantly prolonged with palliative 
chemotherapy.
Traditionally platinum doublets have been the standard 
first-line chemotherapy. Among various different regimens, 
cisplatin and 5-FU is often the regimen of choice because 
of ample experience from oncologists as well as its favorable 
treatment response and tolerability. This popular regimen 
produced an overall response (OR) rate between 66% 
and 78% and a median survival of 12 to 14 months (3-5). 
In particular, Chi et al. revealed that all patients with 
locally recurrent disease responded to cisplatin, 5-FU and 
leucovorin producing a median survival of 34 months, 
while 80% of those with metastatic disease responded 
with a median survival of 14 months (5). This regimen was 
found effective even in patients who had received prior 
chemotherapy. All five patients who had earlier received 
mitoxantrone still responded, suggesting a lack of cross 
resistance. Another four patients with good responses to 
prior induction chemotherapy with cisplatin and 5-FU 
followed by radiotherapy who then developed metastatic 
disease with disease-free intervals greater than 1 year still, 
nevertheless, responded to the same regimen (5). Moreover, 
the toxicity profile is generally favorable with mild 
immunosuppression and peripheral neuropathy. However 
cisplatin-induced nephrotoxicity and ototoxicity were 
of concern, especially in patients who had also received 
cisplatin during their previous definitive chemoradiation. 
Not uncommonly, carboplatin has been used as a substitute 
of cisplatin for advanced head and neck cancers including 
NPC (6). Two older randomized controlled studies on 
advanced head and neck cancers demonstrated that cisplatin 
was superior to carboplatin in terms of improved response 
rate (7,8). One of these showed cisplatin conferred superior 
disease-free survival and overall survival (OS) compared 
to carboplatin when both were used with 5-FU (8). 
However this study did not recruit patients with recurrent 
or metastatic diseases. In 2013, a retrospective Malaysian 
study compared cisplatin and 5-FU with carboplatin and 
5-FU in 41 patients with recurrent and metastatic head and 
neck squamous cell cancer and NPC (9). This showed that 
carboplatin and 5-FU (median survival, 12 months) was not 
inferior to cisplatin and 5-FU (median survival, 10 months; 
P=0.110). However, drawbacks of this study were that no 
subgroup analysis was performed for NPC patients only and 
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there were six treatment-related mortalities (14.6%)—four 
in the carboplatin + 5-FU group and two in the cisplatin + 
5-FU group. All these phase II retrospective and prospective 
trials are not convincing enough to routinely recommend 
PF as a standard regimen in the first-line setting and thus 
a phase III head-to-head randomized-controlled trial is 
definitely indicated to answer this question.
Zhang and colleagues were congratulated for their 
pivotal phase III trial using gemcitabine and cisplatin (GP) 
as first-line treatment for recurrent or metastatic NPC (10). 
This is the first multi-center randomized-controlled trial 
investigating the replacement of 5-FU with gemcitabine 
in addition to cisplatin as 1st line treatment in this setting, 
performed in endemic areas of NPC in 22 hospitals in 
China. The primary study endpoint was progression-free 
survival (PFS) in the intention-to-treat population, while 
secondary endpoints were objective response rate, disease 
control rate, safety profiles and OS. Altogether 362 patients 
were equally randomized to either GP or cisplatin with 5-FU 
(PF) regimen. After a median follow-up of 19.4 months, 
the median PFS was statistically longer in the GP regimen 
(median: 7.0 months) as compared to PF counterpart 
(5.6 months, P<0.0001). Subgroup analysis demonstrated 
that PFS advantage was observed in all prespecified 
subgroups except non-type-III histology and chemotherapy 
with 5 cycles. A higher objective response rate was noted 
in the GP regimen (64%) compared to PF regimen (42%), 
while disease control was similar between the two arms 
(90% versus 86%). With respect to safety profiles, more 
grade ≥3 hematological adverse events were seen in patients 
treated with GP, whereas more mucosal inflammation was 
reported in those who received PF. Finally, OS was also 
significantly longer with GP compared to PF (median: 29.1 
vs. 20.9 months, P=0.0025), though event follow-up is yet 
to mature.
While this is the first head-to-head randomized-
controlled trial demonstrating the superiority of GP to 
PF, there are some caveats pertaining to this study. First 
of all, no stratification factor was employed during the 
randomization process. It has been previously shown that 
presence of liver metastasis is a poor prognostic group 
while lung metastasis is a favorable prognostic factor 
(11-13). Secondly, the usual dose of cisplatin is 100 mg/m2 
given every 3 weeks when it is combined with 5-FU in 
the recurrent/metastatic setting. However, it was set at 
80 mg/m2 in both arms in the current study. It might be 
the intention of the authors to set it at this dose level as 
majority of their patients had been heavily exposed to 
platinum during their prior curative treatment. It is not 
known if this slightly diminished dose of cisplatin would 
carry any impact on tumor response and survival outcomes. 
Though induction chemotherapy was allowed in this 
study, only agents including platinum, 5-FU, docetaxel 
and paclitaxel but not gemcitabine were permitted in this 
setting. The study results may have become insignificant 
if gemcitabine is also allowed in the induction setting, as 
it is getting popularity as shown in recent studies (14-16). 
The current drug of choice may be further complicated 
by the recently published phase III RCT comparing 
induction chemotherapy with docetaxel, cisplatin and 5-FU 
(TPF) followed by concurrent chemoradiotherapy versus 
concurrent chemoradiotherapy (17). The more exposure 
to 5-FU in the induction setting may diminish the efficacy 
when used in recurrent/metastatic diseases.
While chemotherapy is still the mainstay of treatment 
for incurable recurrent or metastatic NPC, novel systemic 
therapies have also been evaluated for the past decade. 
Various targeted therapeutic agents (including cetuximab, 
nimotuzumab, gefitinib, erlotinib, bevacizumab, sorafenib, 
sunitinib, pazopanib, axitinib) have been investigated 
alone or in combination with other chemotherapy drugs. 
However, the results were not impressive, no significant 
superiority in efficacy have been demonstrated.
Finally immunotherapy with immune checkpoint 
inhibitors has gradually emerged as a promising treatment 
modality for head and neck squamous cell carcinoma 
(HNSCC). Pembrolizumab in Keynote-012 phase Ib study, 
was shown to produce an objective response rate of 18%, 
a median PFS of 2 months and a median OS of 13 months 
in the intention-to-treat population (18). This promising 
result has led to accelerated approval by Food and Drug 
Administration of the United States in August this year 
for the treatment of patients with recurrent or metastatic 
HNSCC with disease progression on or after platinum-
containing chemotherapy. More recently, nivolumab 
in the multi-center phase III randomized-controlled 
trial was superior to standard single-agent systemic 
therapy (methotrexate, docetaxel or cetuximab) (19). 
OS as the primary study endpoint was reached (7.5 vs. 
5.1 months, P=0.01). Though median PFS was similar 
between the two arms (2.0 vs. 2.3 months, P=0.32), the 
rate of PFS at 6 months was higher with nivolumab 
(19.7% vs. 9.9%). The objective response rate was also 
more promising (13.3% vs. 5.8%). Perhaps it is prime 
time for these immunotherapeutic agents to be tested in 
NPC. The first phase I study on NPC demonstrated an 
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objective response in 22.2% and disease control in 77.8% 
of a total of 44 patients (20). A least three phase II trials 
are ongoing to investigate their safety and efficacy in the 
recurrent/metastatic setting as second-line treatment or 
beyond after prior failure to platinum-based chemotherapy 
(NCT02339558, NCT02611960 and NCT02605967). 
Hopefully they will provide a new paradigm of treatment 
which can be further extended in the 1st line setting.
In summary, gemcitabine and platinum has become the 
standard first-line treatment for recurrent/metastatic NPC. 
Future research focus should be directed to investigations of 
novel systemic therapies which can supplement or replace 
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